Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 170

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 170
---
 49 consultants. The loss of the services of its Chief Executive Officer or any of its senior management or the inability to hire or retain experienced management personnel could adversely affect its ability to execute its business plan and harm its operating results. In addition, laws and regulations on executive compensation, including legislation in its home country, Switzerland, may restrict its ability to attract, motivate and retain the required level of qualified personnel. In Switzerland, legislation affecting public companies has been passed that, among other things, (i) imposes an annual binding shareholders’ “say -on-pay” vote with respect to the compensation of the members of (a) the senior management and (b) the board of directors, (ii) prohibits severance, advances, transaction premiums and similar payments to senior management and directors, and (iii) requires companies to specify various compensation -relatedmatters in their articles of association, thus requiring them to be approved by a shareholders’ vote. Because of the specialized scientific and managerial nature of its business, NLS relies heavily on its ability to attract and retain qualified scientific and technical consultants. In particular, the loss of one or more of its senior management or key consultants could be detrimental to it if NLS cannot recruit suitable replacements in a timely manner. NLS does not currently carry “key person” insurance on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical industry is intense. Due to this intense competition, NLS may be unable to attract and retain qualified personnel necessary for the development of its business or to recruit suitable replacement personnel. NLS may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If NLS is unable to comply, or have not fully complied, with such laws, NLS could face substantial penalties. If NLS obtains FDA approval for any of its product candidates and begin commercializing those products in the United States, its operations may be directly or indirectly through its customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti -KickbackStatute, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among other things, its proposed sales, marketing and education programs. In addition, NLS may be subject to patient privacy regulation by both the federal government and the states in which NLS conducts its business. The laws that may affect its ability to operate include: •the federal Anti -KickbackStatute, which prohibits,